Technical notes written for the bench: what changes the result, what does not, and how to tell the difference.
Purity, recovery and the caveats — measured samples with the gate strategy written down.
Browse the sectionBench-level explanations: which step changes the result and which does not.
Browse the sectionMechanism-first reading of papers and concepts.
Browse the sectionPapers we read closely, with the method section treated seriously.
Browse the sectionStarting frequency, target abundance and downstream assay decide the format long before brand does. A short rule set with the numbers behind it.
LDL-receptor density, cell-cycle status and envelope choice — and what envelope engineering can and cannot fix.
Purity and recovery from real separations, reported with the sample, the gate and the caveats. The Chinese editions carry the full flow plots; English editions are being published step by step.
Our RV02-20 retroviral vector is cited in the Methods of a 2026 Nature Communications paper on DNMT3A-driven immune evasion in colorectal cancer (Zhao J. et al., Nat Commun 2026;17:10729), where it was used to transduce human CD8⁺ T cells at MOI 5.
Tell us your cell type, sample source and downstream assay — we will suggest an isolation route, a culture condition and the matching catalogue numbers.